Chronic Bronchitis and Emphysema - Smoking-Related Illnesses
There is no doubt that smoking causes other illnesses that ranges from the minor sickness to the most fatal illnesses such as lung cancer and cardiac arrest. But despite of this, smokers worldwide continue to grow worldwide and tobacco manufactures continue to get rich. Smoking related illnesses would not stop smokers from puffing in the deadly substance in cigarettes and tobacco manufacturers will not stop from producing these deadly substances. Are the following smoking related illnesses not fatal enough to make a smoker stop the habit?
Other smoking related diseases are not as rampant as cancer, heart or pulmonary disease but they are nonetheless fatal and enough reason to quit smoking. These smoking related illnesses are high blood pressure, fertility problems, asthma, and eye damages such as cataracts and lost of eyesight, dental problems, ulcers, and over all physical appearance.
- The second most predominant smoking related illness is cancer which does not only affect the lungs but the throat and mouth as well.
- Lung cancer is the deadliest smoking related illness of all and will most likely affect smokers than non-smokers.
- Statistics show that 90% of smokers develop lung cancer and 1 out of ten moderate smokers and 1 out of five heavy smokers will die of lung cancer.
- A scary thought indeed which should be enough to discourage smokers from continuing the habit.
- But apparently not enough.
- Aside from lung cancer, other smoking related illness causing cancer can also be developed due to smoking.
- This includes cancer of the bladder, cancer of the kidneys and cancer of the pancreas.
Lastly, Smokers are Not the Only People Susceptible to Smoking Related Illnesses
Second hand smoke or those people who are exposed to the smoke breathe out by smokers are can also develop smoking related illnesses which can be as fatal with that of the actual smokers. Babies and young children with smoking parents are the most affected by second hand smoke. It is only because that we are rather fluent on the subject of Emphysema Chronic
Bronchitis cough up have ventured on writing something so influential on Emphysema Chronic Bronchitis like this!
Another smoking related illnesses which is getting rampant among smokers is the chronic pulmonary diseases which is due the blocking of airflow and causes difficulty in breathing. Two of the most common chronic pulmonary disease is emphysema and chronic bronchitis. Emphysema is a deadly smoking related illnesses which is due to the damage brought about by smoking to the air sacs. While bronchitis is a smoking related illnesses which is characterized by continuous coughing with mucus for several months. One thing to note about chronic pulmonary diseases is that they occur during the later ages of a smoker's life.
The Most Predominant Smoking Related Illness is Heart Disease
The harmful substances inhaled by smokers harden the arteries which speed up the blood clotting. Once the arteries are clogged cardiovascular diseases called thrombosis which can either be coronary or cerebral. Coronary thrombosis leads to heart attack due to the clogging of the veins supplying blood to the heart. Cerebral thrombosis is caused by the clogging of the veins connected to the brain which can cause collapse, stroke or paralysis. Although there was a lot of fluctuation in the writing styles of we independent writers, we have come up with an end product on Emphysema Chronic Bronchitis worth reading!
The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.
Gastrointestinal Effects
The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients. Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped. Responsibility is what makes a person. So we felt it our responsibility to elaborate more on Chronic Bronchitis so that not only us, but everyone knew more about it!
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications.
Urinary tract infections (norfloxacin, lomefloxacin, enoxacin, ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, trovafloxacin) Lower respiratory tract infections (lomefloxacin, ofloxacin, ciprofloxacin, trovafloxacin) Skin and skin-structure infections (ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin) Urethral and cervical gonococcal infections (norfloxacin, enoxacin, ofloxacin, ciprofloxacin, gatifloxacin, trovafloxacin) Prostatitis (norfloxacin, ofloxacin, trovafloxacin) Acute sinusitis (ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin (Avelox), trovafloxacin) Acute exacerbations of chronic bronchitis (levofloxacin, sparfloxacin (Zagam), gatifloxacin, moxifloxacin, trovafloxacin) Community-acquired pneumonia (levofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, trovafloxacin)
.
Smoking Causes Cancer, Heart Disease, EmphysemaFourth Generation
The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections.
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Thinking of what to do upon reading this article on Bronchitis? Well you can very well use the information constructively by imparting it to others.
First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance. Failure is the stepping stone to success. So if you do fail to understand this article on Chronic Bronchitis, don't fret. Read it again a few times, and you are sure to finally get its meaning.
Side Effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects. Developing a basis for this composition on Chronic
Bronchitis and coughing up task. It took lots of patience and hard work to develop.
Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agentsThe fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. Reading all this about Chronic Bronchitis is sure to help you get a better understanding of Chronic Bronchitis. So make full use of the information we have provided here.
All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance. Chronic Bronchitis are basically interesting parts of our day-to-day life. It is only that sometimes, we are not aware of this fact!
Home
Search
Login
Register